Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

SAMIR ABRAKSIA

NPI
1275638199
CMS profile
329687
Location
CLEVELAND, OH

General Payments · PY2018–2024

$29,625.15

  • Reported across 76 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$1,920.63

14 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $832.50 1
Food and Beverage $793.86 10
Education $294.27 3

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Acerta Pharma LLC $1,082.48 3
Takeda Pharmaceuticals U.S.A., Inc. $238.75 3
BeiGene USA, Inc. $136.49 1
PFIZER INC. $125.00 1
AVEO Pharmaceuticals, Inc. $99.00 1
Lilly USA, LLC $95.28 1
E.R. Squibb & Sons, L.L.C. $88.80 1
Celgene Corporation $32.81 2
ABBVIE INC. $22.02 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $23,813.24 22
PY2019 $518.48 6
PY2020 $436.74 4
PY2021 $1,102.01 12
PY2022 $1,036.08 10
PY2023 $797.97 8
PY2024 $1,920.63 14

Payment records · PY2024 (14)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
ABBVIE INC. $22.02 05/11/2024 Food and Beverage Undisputed 01/23/2026 1103169054 CMS
AstraZeneca Pharmaceuticals LP $832.50 04/01/2024 Consulting Fee Undisputed 01/23/2026 1110555172 CMS
AstraZeneca Pharmaceuticals LP $124.99 10/09/2024 Food and Beverage Undisputed 01/23/2026 1110535246 CMS
AstraZeneca Pharmaceuticals LP $124.99 11/20/2024 Food and Beverage Undisputed 01/23/2026 1110532647 CMS
Aveo Pharmaceuticals, Inc. $99.00 11/20/2024 Education Undisputed 01/23/2026 1143485933 CMS
BeiGene USA, Inc. $136.49 12/12/2024 Food and Beverage Undisputed 01/23/2026 1120854541 CMS
Celgene Corporation $19.07 03/13/2024 Food and Beverage Undisputed 01/23/2026 1101090471 CMS
Celgene Corporation $13.74 05/14/2024 Food and Beverage Undisputed 01/23/2026 1101090475 CMS
E.R. Squibb & Sons, L.L.C. $88.80 06/05/2024 Food and Beverage Undisputed 01/23/2026 1101252046 CMS
Lilly USA, LLC $95.28 04/29/2024 Education Undisputed 01/23/2026 1135411497 CMS
PFIZER INC. $125.00 02/20/2024 Food and Beverage Undisputed 01/23/2026 1131474857 CMS
Takeda Pharmaceuticals U.S.A., Inc. $124.99 01/09/2024 Food and Beverage Undisputed 01/23/2026 1144951976 CMS
Takeda Pharmaceuticals U.S.A., Inc. $99.99 03/21/2024 Education Undisputed 01/23/2026 1144951978 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.77 08/28/2024 Food and Beverage Undisputed 01/23/2026 1144951980 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.